Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Min, Kyung Hoon | - |
dc.contributor.author | Hur, Gyu Young | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Shim, Jae Jeong | - |
dc.contributor.author | Kang, Kyung Ho | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.date.accessioned | 2021-09-05T00:18:14Z | - |
dc.date.available | 2021-09-05T00:18:14Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0009-3157 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96108 | - |
dc.description.abstract | Background: Despite the development of molecular research and targeted therapy, patients with wild-type epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) still receive platinum doublet chemotherapy as the standard first-line treatment. We investigated the efficacy of first-line regimens in patients with wild-type EGFR nonsquamous NSCLC. Methods: We retrospectively analyzed the efficacy of various platinum doublet regimens as first-line treatments. Between 2007 and 2013, a total of 165 patients with wild-type EGFR nonsquamous NSCLC were included in this study. Results: Seventy-one (43.0%) patients were treated with pemetrexed plus platinum (PP) and 94 (57.0%) with non-pemetrexed plus platinum (NPP). The overall response rate was not different between the PP- and NPP-treated groups (26.8 vs. 28.7%, respectively; p = 0.78). The median progression-free survival (PFS) and overall survival (OS) also showed no differences between the two treatment groups (p = 0.12 for PFS, p = 0.42 for OS). The median PFS and OS for the PP group were 4.6 months (95% CI, 3.8-5.4) and 18.7 months (95% CI, 11.7-25.8), respectively, and for the NPP group, they were 4.2 months (95% CI, 3.4-5.0) and 12.2 months (95% CI, 10.3-14.1), respectively. In the subgroup analysis, most subgroups showed no significant difference in PFS and OS between the two treatment groups. Conclusion: Our data showed that the efficacy of various platinum doublet regimens was similar in patients with wild-type EGFR nonsquamous NSCLC. (C) 2015 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | PHASE-III | - |
dc.subject | OPEN-LABEL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | GEFITINIB | - |
dc.subject | SURVIVAL | - |
dc.subject | EGFR | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | MULTICENTER | - |
dc.subject | GEMCITABINE | - |
dc.subject | METAANALYSIS | - |
dc.title | Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.contributor.affiliatedAuthor | Min, Kyung Hoon | - |
dc.contributor.affiliatedAuthor | Hur, Gyu Young | - |
dc.contributor.affiliatedAuthor | Lee, Sung Yong | - |
dc.contributor.affiliatedAuthor | Shim, Jae Jeong | - |
dc.contributor.affiliatedAuthor | Kang, Kyung Ho | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.identifier.doi | 10.1159/000440941 | - |
dc.identifier.scopusid | 2-s2.0-84946742779 | - |
dc.identifier.wosid | 000366735400007 | - |
dc.identifier.bibliographicCitation | CHEMOTHERAPY, v.61, no.1, pp.41 - 50 | - |
dc.relation.isPartOf | CHEMOTHERAPY | - |
dc.citation.title | CHEMOTHERAPY | - |
dc.citation.volume | 61 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 41 | - |
dc.citation.endPage | 50 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordAuthor | Epidermal growth factor receptor | - |
dc.subject.keywordAuthor | First-line chemotherapy | - |
dc.subject.keywordAuthor | Non-small cell lung carcinoma | - |
dc.subject.keywordAuthor | Wild type | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.